10 Unusual Stocks Attracting Huge Interest In The Pre-Market Right Now

Sniper

Here’s where we see the heat today:

Adobe bought by Microsoft? Genzyme hunts for a new acquirer, Kulicke is dropping like a rock on bad revenue guidance, and more…

PHARMA CATALYST: Onyx (ONXX) gets request for more data on a cancer treatment, stock tanking

REVENUE DIVE: Kulicke & Soffa (KLIC) dropping hard after saying Q1 2011 revenue will be lower than Q4

M&A: Johnson & Johnson has said they will buy Crucell (CRXL), still massive volume in the shares

Probably the M&A arbitrage players. Read about the deal here.

PHARMA CATALYST: Avanir (AVNR) has a major FDA decision coming on October 29th

Shares are already seeing action. Read about the FDA decision here.

DOWNGRADE: F5 Networks (FFIV) dropping after its price target was cut by Goldman.

Worth a look.

JOINING THE S&P SMALL CAP INDEX: Atlantic Telenetwork (ATNI) popping after S&P says ATNI will join their small cap index

ODD: Atlas Energy (ATLS) tanking

Is it because law firms are targeting companies such as itself? Read about it here.

CAPITAL STRUCTURE: Cytori Therapeutics (CYTX) tanking after pricing its public offering at just $4.50 per share

M&A: Genzyme (GENZ) is looking for other potential acquirers

TENDER OFFER: Offer for Rescare (RSCR) shares begins, at $13.25 per share

EARNINGS: Seagate (STX) reports, jumping

PHARMA CATALYST: Onyx (ONXX) gets request for more data on a cancer treatment, stock tanking

NOW WATCH: Money & Markets videos

Business Insider Emails & Alerts

Site highlights each day to your inbox.

Follow Business Insider Australia on Facebook, Twitter, LinkedIn, and Instagram.